Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03791060 · ClinicalTrials.gov registry record · Phase 2
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03791060 is a Phase 2 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT03791060, a Phase 2 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).
Interventions
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-04-03 |
| Est. Completion | 2021-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03791060
The ClinicalTrials.gov registry entry for NCT03791060 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT03791060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03791060 about?
NCT03791060 is a clinical study titled "Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)". This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).
What is the current status of trial NCT03791060?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-04-03. Estimated completion is 2021-04-10.
What interventions are being tested in trial NCT03791060?
The interventions under investigation include: Secukinumab (DRUG).
Who is sponsoring clinical trial NCT03791060?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.